- September 28, 2015
A molecule isolated from sea sponges and synthesized at Harvard can halt the growth of cancerous cells.
- August 19, 2015
Twelve advanced research projects aimed at developing new therapies and diagnostics receive support in 2015-16 from Harvard’s Blavatnik Biomedical Accelerator.
Five outstanding HBS alumni will work with inventors from Harvard University’s research laboratories to promote the commercialization of innovative life science-oriented technologies with significant market potential.
- March 04, 2015
NEWTON, Mass.--(BUSINESS WIRE)--Macrolide Pharmaceuticals, a new company with groundbreaking technology to develop novel antibiotics, completed a Series A financing of $22 million led by Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing follows a worldwide license agreement between Harvard's Office of Technology Development and the company, providing exclusive rights to the technology.
With the help of the Blavatnik Biomedical Accelerator, innovators like Chenghua Gu and David Sinclair are advancing their research with an eye on commercial partnership.
Page 3 of 5